V čase prebiehajúcej koronavírusovej pandémie sa často stretávame s pacientmi s covid pozitivitou a závažným nálezom na koronárnych tepnách. Problémoví sú najmä pacienti, ktorí vyžadujú kardiochirurgickú liečbu. U týchto pacientov je dôležitá multidisciplinárna diskusia s posúdením únosnosti operačného výkonu a zvážením najvhodnejšieho prístupu vzhľadom na vyššie mortalitné riziko operačnej liečby. V práci prezentujeme prípad vysokorizikovej covid pozitívnej symptomatickej pacientky s akútnym koronárnym syndrómom, s kritickým kalcifikovaným postihnutím hlavného kmeňa ľavej koronárnej tepny. Pacientka bola nevhodná na kardiochirurgickú liečbu a bola riešená perkutánnou koronárnou intervenciou s použitím ľavokomorovej mechanickej podpory a intravaskulárnej litotripsie.

At the time of the ongoing coronavirus pandemic, we are encountering patients who are Covid-19 positive and have severe coronary artery disease. Patients requiring cardiac surgery are particularly challenging. A multidisciplinary discussion aimed at assessing surgery tolerability and considering the most appropriate approach is important given the higher risk of surgical mortality. We report a case of a high-risk Covid-19 positive symptomatic female patient with an acute coronary syndrome and a critical calcified stenosis of the main stem of the left coronary artery. This patient was not suitable for cardiac surgery and she underwent a percutaneous coronary intervention using a left ventricular mechanical support system and intravascular lithotripsy.

• MeSH
• akutní koronární syndrom chirurgie   MeSH
• COVID-19 komplikace   MeSH
• komorbidita MeSH
• koronární angioplastika * metody   MeSH
• laserová litotripse metody   MeSH
• lidé MeSH
• rizikové faktory MeSH
• senioři MeSH
• vaskulární kalcifikace chirurgie   MeSH
• Check Tag
• lidé MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

To document the real-world experience with the use of pneumatic pulsatile mechanical circulatory support (MCS) with the PulseCath iVAC2L during high-risk percutaneous coronary interventions (HR-PCIs). Background: The use of MCS in HR-PCIs may reduce the rate of major adverse cardiovascular events (MACEs) at 90 days. The PulseCath iVAC2L is a short-term pulsatile transaortic left ventricular (LV) assist device that has been in use since 2014. The iVAC2L Registry tracks its safety and efficacy in a variety of hospitals worldwide. Methods: The iVAC2L Registry is a multicenter, observational registry that aggregates clinical data from patients treated with the iVAC2L worldwide. A total of 293 consecutive cases were retrospectively collected and analyzed. Estimated rates of in-hospital clinical endpoints were described. All-cause mortality was used as the primary endpoint and other outcomes of interest were used as secondary endpoints. The rates obtained were reported and contextualized. Results: The in-hospital rate of all-cause mortality was 1.0%, MACE was 3.1%. Severe hypotension occurred in 8.9% of patients. Major bleeding and major vascular complications occurred in 1.0% and 2.1%, respectively. Acute myocardial infarction occurred in 0.7% of patients. Cerebrovascular events occurred in 1.4% of patients. Cardiac arrest occurred in 1.7% of patients. A statistically significant improvement in blood pressure was observed with iVAC2L activation. Conclusions: The results of the present study suggest that the iVAC2L is capable of improving hemodynamics with a low rate of adverse events. However, confirmatory studies are needed to validate these findings.

• Publikační typ
• časopisecké články MeSH